ANAB Valuation
AnaptysBio Inc
$
21.100
- Overview
- Forecast
- Valuation
ANAB Relative Valuation
ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANAB is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for ANAB's competitors is 28.54, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of 12.08, which is -57.69% above the industry average. Given its robust revenue growth of 286.84%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
BIGC
Bigcommerce Holdings Inc
5.060
USD
-0.59%
PHAT
Phathom Pharmaceuticals Inc
4.380
USD
-0.23%
GFR
Greenfire Resources Ltd
4.470
USD
-1.11%
CHPT
ChargePoint Holdings Inc
0.697
USD
0.00%
XERS
Xeris Biopharma Holdings Inc
5.080
USD
+4.31%
TRDA
Entrada Therapeutics Inc
8.240
USD
+2.87%
GBLI
Global Indemnity Group LLC
30.950
USD
-0.42%
GDOT
Green Dot Corp
9.490
USD
+1.71%
BHB
Bar Harbor Bankshares
30.490
USD
-0.29%
CBNK
Capital Bancorp Inc
33.630
USD
+2.25%
FAQ
Is AnaptysBio Inc (ANAB) currently overvalued or undervalued?
AnaptysBio Inc (ANAB) is now in the Fair zone, suggesting that its current forward PS ratio of 12.08 is considered Fairly compared with the five-year average of 29.61. The fair price of AnaptysBio Inc (ANAB) is between 18.25 to 87.47 according to relative valuation methord.
What is AnaptysBio Inc (ANAB) fair value?
How does ANAB's valuation metrics compare to the industry average?
What is the current P/B ratio for AnaptysBio Inc (ANAB) as of May 21 2025?
What is the current FCF Yield for AnaptysBio Inc (ANAB) as of May 21 2025?
What is the current Forward P/E ratio for AnaptysBio Inc (ANAB) as of May 21 2025?